# Pfizer revenue entity: /record/pfizer.md predicate: revenue page: /record/pfizer/revenue as_of: 2026-11-10 cite: AsOf. "Pfizer quarterly revenue: 16,583,000,000 United States dollar", as of 2026-09-27. Claim clm_F01F5C40574B, https://asof.is/claim/clm_F01F5C40574B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm. As of November 10, 2026, the latest revenue figure on the AsOf record for Pfizer is $16.58 billion for the quarter ended September 27, 2026, from a primary source (sec.gov). Pfizer's latest full-year revenue is $62.58 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 17 claims on Pfizer's revenue, 1 open and 16 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest revenue The newest figure for a shorter period, the quarter ended September 27, 2026: a quarterly_revenue claim, kept apart from the full-year series. Every quarterly revenue figure: /record/pfizer/quarterly_revenue.md - [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,583,000,000 United States dollar | valid 2026-09-27 to present | conf 0.95 | valid | [clm_F01F5C40574B](/claim/clm_F01F5C40574B.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm ## Latest full-year revenue What the record asserts on 2026-11-10. - [Pfizer](/record/pfizer.md) | revenue | 62,579,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_55A653F47AF3](/claim/clm_55A653F47AF3.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Pfizer](/record/pfizer.md) | revenue | 48,418,000,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_1F836D2FE95A](/claim/clm_1F836D2FE95A.md) | [clm_495E00A572C1](/claim/clm_495E00A572C1.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm - [Pfizer](/record/pfizer.md) | revenue | 48,296,000,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_A65C4083AE17](/claim/clm_A65C4083AE17.md) | [clm_1F836D2FE95A](/claim/clm_1F836D2FE95A.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm - [Pfizer](/record/pfizer.md) | revenue | 50,009,000,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_F12BB6E4F260](/claim/clm_F12BB6E4F260.md) | [clm_A65C4083AE17](/claim/clm_A65C4083AE17.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm - [Pfizer](/record/pfizer.md) | revenue | 67,809,000,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_4853ED0711DB](/claim/clm_4853ED0711DB.md) | [clm_F12BB6E4F260](/claim/clm_F12BB6E4F260.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm - [Pfizer](/record/pfizer.md) | revenue | 67,425,000,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_86543AFFE2B5](/claim/clm_86543AFFE2B5.md) | [clm_4853ED0711DB](/claim/clm_4853ED0711DB.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm - [Pfizer](/record/pfizer.md) | revenue | 58,986,000,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_FB18F4B76697](/claim/clm_FB18F4B76697.md) | [clm_86543AFFE2B5](/claim/clm_86543AFFE2B5.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm - [Pfizer](/record/pfizer.md) | revenue | 51,584,000,000 United States dollar | valid 2013-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_032BE9565D4B](/claim/clm_032BE9565D4B.md) | [clm_FB18F4B76697](/claim/clm_FB18F4B76697.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm - [Pfizer](/record/pfizer.md) | revenue | 52,824,000,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_C3C550AB2D1A](/claim/clm_C3C550AB2D1A.md) | [clm_032BE9565D4B](/claim/clm_032BE9565D4B.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm - [Pfizer](/record/pfizer.md) | revenue | 52,546,000,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_052E7C8C40A7](/claim/clm_052E7C8C40A7.md) | [clm_C3C550AB2D1A](/claim/clm_C3C550AB2D1A.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm - [Pfizer](/record/pfizer.md) | revenue | 53,647,000,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_39A482B707D0](/claim/clm_39A482B707D0.md) | [clm_052E7C8C40A7](/claim/clm_052E7C8C40A7.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm - [Pfizer](/record/pfizer.md) | revenue | 51,750,000,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_E33934BCDEB6](/claim/clm_E33934BCDEB6.md) | [clm_39A482B707D0](/claim/clm_39A482B707D0.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm - [Pfizer](/record/pfizer.md) | revenue | 41,651,000,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_CF1DC7D31DB2](/claim/clm_CF1DC7D31DB2.md) | [clm_E33934BCDEB6](/claim/clm_E33934BCDEB6.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm - [Pfizer](/record/pfizer.md) | revenue | 81,288,000,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_76057CE24462](/claim/clm_76057CE24462.md) | [clm_CF1DC7D31DB2](/claim/clm_CF1DC7D31DB2.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm - [Pfizer](/record/pfizer.md) | revenue | 100,330,000,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_E6A536D7125D](/claim/clm_E6A536D7125D.md) | [clm_76057CE24462](/claim/clm_76057CE24462.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm - [Pfizer](/record/pfizer.md) | revenue | 58,496,000,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_0D26120DBD16](/claim/clm_0D26120DBD16.md) | [clm_E6A536D7125D](/claim/clm_E6A536D7125D.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm - [Pfizer](/record/pfizer.md) | revenue | 63,627,000,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_55A653F47AF3](/claim/clm_55A653F47AF3.md) | [clm_0D26120DBD16](/claim/clm_0D26120DBD16.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm - [Pfizer](/record/pfizer.md) | revenue | 62,579,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_55A653F47AF3](/claim/clm_55A653F47AF3.md) sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm ## What replaced what - $48.42 billion (2007-12-31 to 2008-12-31, [clm_495E00A572C1](/claim/clm_495E00A572C1.md)) was replaced by $48.3 billion from 2008-12-31 ([clm_1F836D2FE95A](/claim/clm_1F836D2FE95A.md)) - $48.3 billion (2008-12-31 to 2009-12-31, [clm_1F836D2FE95A](/claim/clm_1F836D2FE95A.md)) was replaced by $50.01 billion from 2009-12-31 ([clm_A65C4083AE17](/claim/clm_A65C4083AE17.md)) - $50.01 billion (2009-12-31 to 2010-12-31, [clm_A65C4083AE17](/claim/clm_A65C4083AE17.md)) was replaced by $67.81 billion from 2010-12-31 ([clm_F12BB6E4F260](/claim/clm_F12BB6E4F260.md)) - $67.81 billion (2010-12-31 to 2011-12-31, [clm_F12BB6E4F260](/claim/clm_F12BB6E4F260.md)) was replaced by $67.43 billion from 2011-12-31 ([clm_4853ED0711DB](/claim/clm_4853ED0711DB.md)) - $67.43 billion (2011-12-31 to 2012-12-31, [clm_4853ED0711DB](/claim/clm_4853ED0711DB.md)) was replaced by $58.99 billion from 2012-12-31 ([clm_86543AFFE2B5](/claim/clm_86543AFFE2B5.md)) - $58.99 billion (2012-12-31 to 2013-12-31, [clm_86543AFFE2B5](/claim/clm_86543AFFE2B5.md)) was replaced by $51.58 billion from 2013-12-31 ([clm_FB18F4B76697](/claim/clm_FB18F4B76697.md)) - $51.58 billion (2013-12-31 to 2016-12-31, [clm_FB18F4B76697](/claim/clm_FB18F4B76697.md)) was replaced by $52.82 billion from 2016-12-31 ([clm_032BE9565D4B](/claim/clm_032BE9565D4B.md)) - $52.82 billion (2016-12-31 to 2017-12-31, [clm_032BE9565D4B](/claim/clm_032BE9565D4B.md)) was replaced by $52.55 billion from 2017-12-31 ([clm_C3C550AB2D1A](/claim/clm_C3C550AB2D1A.md)) - $52.55 billion (2017-12-31 to 2018-12-31, [clm_C3C550AB2D1A](/claim/clm_C3C550AB2D1A.md)) was replaced by $53.65 billion from 2018-12-31 ([clm_052E7C8C40A7](/claim/clm_052E7C8C40A7.md)) - $53.65 billion (2018-12-31 to 2019-12-31, [clm_052E7C8C40A7](/claim/clm_052E7C8C40A7.md)) was replaced by $51.75 billion from 2019-12-31 ([clm_39A482B707D0](/claim/clm_39A482B707D0.md)) - $51.75 billion (2019-12-31 to 2020-12-31, [clm_39A482B707D0](/claim/clm_39A482B707D0.md)) was replaced by $41.65 billion from 2020-12-31 ([clm_E33934BCDEB6](/claim/clm_E33934BCDEB6.md)) - $41.65 billion (2020-12-31 to 2021-12-31, [clm_E33934BCDEB6](/claim/clm_E33934BCDEB6.md)) was replaced by $81.29 billion from 2021-12-31 ([clm_CF1DC7D31DB2](/claim/clm_CF1DC7D31DB2.md)) - $81.29 billion (2021-12-31 to 2022-12-31, [clm_CF1DC7D31DB2](/claim/clm_CF1DC7D31DB2.md)) was replaced by $100.33 billion from 2022-12-31 ([clm_76057CE24462](/claim/clm_76057CE24462.md)) - $100.33 billion (2022-12-31 to 2023-12-31, [clm_76057CE24462](/claim/clm_76057CE24462.md)) was replaced by $58.5 billion from 2023-12-31 ([clm_E6A536D7125D](/claim/clm_E6A536D7125D.md)) - $58.5 billion (2023-12-31 to 2024-12-31, [clm_E6A536D7125D](/claim/clm_E6A536D7125D.md)) was replaced by $63.63 billion from 2024-12-31 ([clm_0D26120DBD16](/claim/clm_0D26120DBD16.md)) - $63.63 billion (2024-12-31 to 2025-12-31, [clm_0D26120DBD16](/claim/clm_0D26120DBD16.md)) was replaced by $62.58 billion from 2025-12-31 ([clm_55A653F47AF3](/claim/clm_55A653F47AF3.md)) ## Questions this record answers ### What is Pfizer's current revenue? The latest figure on the record is $16.58 billion for the quarter ended September 27, 2026, from a primary source (sec.gov). The latest full-year figure is $62.58 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 10, 2026. ### What was Pfizer's revenue for the quarter ended September 27, 2026? $16.58 billion for the quarter ended September 27, 2026, dated September 27, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Pfizer's revenue last change? The latest value on the record is $62.58 billion, dated December 31, 2025; before it the record holds $63.63 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Pfizer's revenue before $62.58 billion? $63.63 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/pfizer/revenue (markdown: /record/pfizer/revenue.md) - Entity twin: /record/pfizer.md ยท timeline: /timelines/pfizer.md - Every company's revenue: /facts/revenue.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.